FDA Approves BeiGene’s Brukinsa to Treat Adults with Mantle Cell Lymphoma
News
The U.S. Food and Drug Administration (FDA) has granted conditional approval to BeiGene’s Brukinsa (zanubrutinib) as a second-line treatment for adults with mantle cell lymphoma (MCL) who have received at least ... Read more